East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cefixime Capsules. Aurobindo Pharma’s Cefixime Capsules, is an AB-rated generic equivalent to the reference listed drug (RLD), Suprax^® Capsules, manufactured by Lupin Limited.

Cefixime Capsules, 400 mg are indicated in the treatment of adults and pediatric patients six months and older with the following infections :

• Uncomplicated Urinary Tract Infections
• Pharyngitis and Tonsillitis
• Acute Exacerbations of Chronic Bronchitis
• Uncomplicated Gonorrhea (cervical/urethral)